Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00763139 · ClinicalTrials.gov registry record · NA

Inflammation and Insulin Resistance in Rheumatoid Arthritis

A NA study, sponsored by Vanderbilt University.

Completed
Registry status
NA
Development phase
34
Enrollment target

NCT00763139: Completed NA study, sponsored by Vanderbilt University.

NCT00763139 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 34 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00763139, a NA study, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
NA
Development phase
34 participants
Enrollment target

Study Summary

Rheumatoid arthritis (RA) is a form of arthritis that causes pain, swelling, stiffness, and loss of function in the joints. Over time, joint deformity, joint destruction, and loss of function can occur. Current treatment aims to improve symptoms, but there is no cure for the disease. Pioglitazone is drug that is effective in treating people with diabetes. This study will determine whether pioglitazone can also be used to effectively treat people with RA.

Primary Outcome

A measure of disease activity based upon tender joint count of 28 joints, swollen joint count of 28 joints, erythrocyte sedimentation rate, and global disease activity (GH) as reported by participant. Calculation is as follows: DAS28=0.56\*sqrt(t28) + 0.28\*sqrt(sw28) + 0.70\*Ln(ESR) + 0.014\*GH

Interventions

  • DRUG Placebo
  • DRUG Pioglitazone

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2009-04
Est. Completion 2013-12
Phase NA
Vanderbilt University

430 total trials

What the finished NCT00763139 record still lists

NCT00763139 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00763139 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00763139 about?

NCT00763139 is a clinical study titled "Inflammation and Insulin Resistance in Rheumatoid Arthritis". Rheumatoid arthritis (RA) is a form of arthritis that causes pain, swelling, stiffness, and loss of function in the joints. Over time, joint deformity, joint destruction, and loss of function can occur. Current treatment aims to improve symptoms, but there is no cure for the disease. Pioglitazone is...

What is the current status of trial NCT00763139?

This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2009-04. Estimated completion is 2013-12.

What interventions are being tested in trial NCT00763139?

The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG).

Who is sponsoring clinical trial NCT00763139?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00763139's enrollment target sits among peer trials

34 1570th of 2000 higher than 427 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00763139, the US trial registry maintained by the National Library of Medicine. NCT00763139 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.